Long-term treatment with intravenous bisphosphonates in metastatic breast cancer: A retrospective study

Breast Journal

Volumn 19, Issue 5, 2013, Pages 504-511

  Brufsky, Adam M ^a   Sereika, Susan M ^b,c   Mathew, Aju ^a   Tomifumi, Onishi ^a   Singh, Vikramjit ^a   Rosenzweig, Margaret ^c  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

adverse events; bisphosphonate; breast cancer; pamidronate; zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE METASTASIS; BREAST METASTASIS; COHORT ANALYSIS; CONTROLLED STUDY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; JAW OSTEONECROSIS; KIDNEY FAILURE; KIDNEY FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADVERSE EVENTS; BISPHOSPHONATE; BREAST CANCER; PAMIDRONATE; ZOLEDRONIC ACID;

ADULT; AGED; AGED, 80 AND OVER; BISPHOSPHONATE-ASSOCIATED OSTEONECROSIS OF THE JAW; BONE NEOPLASMS; BREAST NEOPLASMS; COHORT STUDIES; DIPHOSPHONATES; FEMALE; HUMANS; INCIDENCE; INJECTIONS, INTRAVENOUS; KIDNEY DISEASES; MIDDLE AGED; RETROSPECTIVE STUDIES;

EID: 84884903605     PISSN: 1075122X     EISSN: 15244741     Source Type: Journal    
DOI: 10.1111/tbj.12152     Document Type: Article

References (36)

1. American Cancer Society. Breast Cancer Facts & Figures 2009-2010. Atlanta, GA: American Cancer Society Inc, 2009. Available at: http://www.cancer.org/acs/groups/content/@nho/documents/document/ f861009final90809pdf.pdf (accessed November 3, 2011).
2. Coleman RE,. Adjuvant bisphosphonates in breast cancer: are we witnessing the emergence of a new therapeutic strategy? Eur J Cancer 2009; 45: 1909-15.
3. Costa L, Badia X, Chow E, et al,. Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer 2008; 16: 879-89.
4. Ross JR, Saunders Y, Edmonds PM, et al,. Systematic review of role of bisphosphonates on skeletal morbidity in metastatic cancer. BMJ 2003; 327: 469.
5. Rosen LS, Gordon D, Kaminski M, et al,. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377-87.
6. Rosen LS, Gordon D, Kaminski M, et al,. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003; 98: 1735-44.
7. Gainford MC, Dranitsaris G, Clemons M,. Recent developments in bisphosphonates for patients with metastatic breast cancer. BMJ 2005; 330: 769-73.
8. Xgeva (denosumab) [package insert]. Thousand Oaks, CA: Amgen Inc, 2010.
9. Fizazi K, Carducci M, Smith M, et al,. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 2011; 377: 813-22.
10. Henry DH, Costa L, Goldwasser F, et al,. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol 2011; 29: 1125-32.
11. Stopeck AT, Lipton A, Body JJ, et al,. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol 2010; 28: 5132-9.
12. Rosen LS, Gordon D, Tchekmedyian S, et al,. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: a phase III, double-blind, randomized trial-the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol 2003; 21: 3150-7.
13. Zuradelli M, Masci G, Biancofiore G, et al,. High incidence of hypocalcemia and serum creatinine increase in patients with bone metastases treated with zoledronic acid. Oncologist 2009; 14: 548-56.
14. McDermott RS, Kloth DD, Wang H, et al,. Impact of zoledronic acid on renal function in patients with cancer: clinical significance and development of a predictive model. J Support Oncol 2006; 4: 524-9.
15. Kohno N, Aogi K, Minami H, et al,. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 2005; 23: 3314-21.
16. Ali SM, Esteva FJ, Hortobagyi G, et al,. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001; 19: 3434-7.
17. Van Poznak CH, Temin S, Yee GC, et al,. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011; 29: 1221-7.
18. Zometa (zoledronic acid) [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2011.
19. Aredia [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corporation, 2008.
20. Department of Health and Human Services. Approval letter for application number NDA 21-223/S-009 & S-010. Rockville, MD: Food and Drug Administration. Published January 31, 2005. Available at: http://theoncologist. alphamedpress.org/site/misc/Zometa-FDA-Ltr-David-Orloff.pdf (accessed November 3, 2011).
21. Department of Health and Human Services. Approval letter for application number NDA 20-036/S-034. Rockville, MD: Food and Drug Administration. Published December 11, 2007. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/ appletter/2007/020036s034ltr.pdf (accessed November 3, 2011).
22. Almazrooa SA, Woo SB,. Bisphosphonate and nonbisphosphonate-associated osteonecrosis of the jaw: a review. J Am Dent Assoc 2009; 140: 864-75.
23. Sambrook P, Olver I, Goss A,. Bisphosphonates and osteonecrosis of the jaw. Aust Fam Physician 2006; 35: 801-3.
24. Newcombe RG,. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17: 857-72.
25. Wilson E,. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc 1927; 22: 209-12.
26. Bamias A, Kastritis E, Bamia C, et al,. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005; 23: 8580-7.
27. Hoff AO, Toth BB, Altundag K, et al,. Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res 2008; 23: 826-36.
28. Wang EP, Kaban LB, Strewler GJ, et al,. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J Oral Maxillofac Surg 2007; 65: 1328-31.
29. Corso A, Varettoni M, Zappasodi P, et al,. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma. Leukemia 2007; 21: 1545-8.
30. Lacy MQ, Dispenzieri A, Gertz MA, et al,. Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006; 81: 1047-53.
31. Morgan G,. MRC Myeloma IX Trial-Characterising the biologic and temporal basis of efficacy of long-term bisphosphonate treatment in patients with multiple myeloma [oral presentation]. Presented at: 2011 European Multidisciplinary Cancer Congress; September 23-27, 2011; Stockholm, Sweden. Abstract 9202.
32. Dimopoulos MA, Kastritis E, Bamia C, et al,. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 2009; 20: 117-20.
33. Ripamonti CI, Maniezzo M, Campa T, et al,. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009; 20: 137-45.
34. Aragon-Ching JB, Ning YM, Chen CC, et al,. Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 2009; 27: 221-6.
35. Wildiers H, Duck L, Delforge M, et al,. Baseline characteristics, prior bisphosphonate (BPH) therapy (Rx), and clinical parameters of patients in LOTUZ, a prospective pharmacoepidemiological study of long-term zoledronic acid (ZOL) treatment (>2 years) in patients (pts) with solid and hematologic malignancies. J Clin Oncol 2008; 26: 732s. Abstract 20597.
36. Coleman R, Brown J, Terpos E, et al,. Bone markers and their prognostic value in metastatic bone disease: clinical evidence and future directions. Cancer Treat Rev 2008; 34: 629-39.